Learning versus confirming in clinical drug development (Q41400590)

30 September 2017

1 reference

title

Learning versus confirming in clinical drug development (English)

1 reference

30 September 2017

Sheiner LB

1

1 reference

PubMed ID

9084453

30 September 2017

language of work or name

English

0 references

publication date

1 March 1997

1 reference

Clinical Pharmacology & Therapeutics

30 September 2017

1 reference

30 September 2017

61

1 reference

30 September 2017

3

1 reference

30 September 2017

275-291

1 reference

Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software.

30 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Use and Abuse of Regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

The intellectual health of clinical drug evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Practical implications of modes of statistical inference for causal effects and the critical role of the assignment mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Intention-to-treat analysis and the goals of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Estimating the minimum therapeutically effective dose of a compound via regression modelling and percentile estimation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

A simulation study comparing designs for dose ranging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Bayesian methods for phase I clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Monotone smoothing with application to dose-response curves and the assessment of synergism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Mixed-effects nonlinear regression for unbalanced repeated measures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Theophylline target concentration in severe airways obstruction - 10 or 20 mg/L? A randomised concentration-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

The randomized concentration-controlled trial: An evaluation of its sample size efficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction. Population analysis of a randomised concentration controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

The state of drug development in the United States in 1990: a view from the academic community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Trimetrexate: a critical appraisal of the phase II clinical trial experience: evidence of drug discovery-clinical development disjunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Pharmacologically guided phase I clinical trials based upon preclinical drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Clinical pharmacology and the choice between theory and empiricism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Applying Bayesian ideas in drug development and clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Experimental design for drug development: a Bayesian approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Effect of age and gender on tirilazad pharmacokinetics in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Simultaneous modeling of the pharmacokinetics and pharmacodynamics of midazolam and diazepam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2897%2990160-0

10.1016/S0009-9236(97)90160-0

7 January 2021

Identifiers

DOI

1 reference

30 September 2017

1 reference

PubMed ID

9084453